{"disease":{"id":"prophylaxis","name":"prophylaxis"},"drugs":{"marketed":[{"drug_id":"chembl-chembl48361","indication_name":"Prophylaxis of DVT and PE after hip replacement surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dabigatran Etexilate","generic_name":"DABIGATRAN","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":"1200","mechanism":"Dabigatran works by directly inhibiting the activity of thrombin, a key enzyme in the blood clotting process."},{"drug_id":"fragmin","indication_name":"Prophylaxis of Ischemic Complications in Unstable Angina and Non-Q-Wave MI","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fragmin","generic_name":"Dalteparin Sodium","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Factor Xa and thrombin","drug_class":"Low molecular weight heparin (LMWH)","quality_score":68,"revenue":null,"mechanism":"Dalteparin enhances inhibition of Factor Xa and thrombin by antithrombin."},{"drug_id":"fragmin","indication_name":"Prophylaxis of DVT in Abdominal Surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fragmin","generic_name":"Dalteparin Sodium","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Factor Xa and thrombin","drug_class":"Low molecular weight heparin (LMWH)","quality_score":68,"revenue":null,"mechanism":"Dalteparin enhances inhibition of Factor Xa and thrombin by antithrombin."},{"drug_id":"fragmin","indication_name":"Prophylaxis of DVT in Hip Replacement Surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fragmin","generic_name":"Dalteparin Sodium","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Factor Xa and thrombin","drug_class":"Low molecular weight heparin (LMWH)","quality_score":68,"revenue":null,"mechanism":"Dalteparin enhances inhibition of Factor Xa and thrombin by antithrombin."},{"drug_id":"fragmin","indication_name":"Prophylaxis of DVT in Medical Patients with Restricted Mobility","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fragmin","generic_name":"Dalteparin Sodium","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Factor Xa and thrombin","drug_class":"Low molecular weight heparin (LMWH)","quality_score":68,"revenue":null,"mechanism":"Dalteparin enhances inhibition of Factor Xa and thrombin by antithrombin."},{"drug_id":"garadacimab-gxii","indication_name":"Prophylaxis for HAE","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ANDEMBRY","generic_name":"GARADACIMAB-GXII","company_name":"CSL BEHRING LLC","drug_phase":"marketed","molecular_target":"activated Factor XII (FXIIa and βFXIIa)","drug_class":"","quality_score":41,"revenue":null,"mechanism":"Garadacimab-gxii inhibits activated FXII, reducing the activation of prekallikrein and bradykinin generation, thereby decreasing inflammation and swelling in HAE attacks."},{"drug_id":"donidalorsen","indication_name":"Prophylaxis for HAE attacks","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dawnzera","generic_name":"DONIDALORSEN","company_name":"Ionis Pharms Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":47,"revenue":null,"mechanism":"Dawnzera works by binding to a specific messenger RNA molecule to prevent the production of a faulty protein that causes hereditary angioedema."},{"drug_id":"cefoxitin","indication_name":"Prophylaxis of infection in surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mefoxin In Sodium Chloride 0.9% In Plastic Container","generic_name":"CEFOXITIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"dabigatran-etexilate","indication_name":"Prophylaxis of DVT and PE after hip replacement surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pradaxa","generic_name":"dabigatran-etexilate","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Thrombin (serine protease)","drug_class":"Direct thrombin inhibitor","quality_score":71,"revenue":null,"mechanism":"Competitive direct thrombin inhibitor preventing fibrin formation and thrombus development."},{"drug_id":"fluconazole","indication_name":"Prophylaxis of candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diflucan","generic_name":"fluconazole","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase","drug_class":"Azole Antifungal [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"cefoxitin-sodium","indication_name":"Prophylaxis of infection in surgical procedures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFOXITIN SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":21,"revenue":null,"mechanism":null},{"drug_id":"hydroxychloroquine","indication_name":"Malaria prophylaxis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hydroxychloroquine Sulfate","generic_name":"HYDROXYCHLOROQUINE","company_name":"Advanz","drug_phase":"marketed","molecular_target":"Toll-like receptor 9","drug_class":"Antimalarial","quality_score":75,"revenue":null,"mechanism":"Hydroxychloroquine Sulfate works by interfering with the replication of malaria parasites and reducing inflammation in the body."},{"drug_id":"niacin","indication_name":"Fluoride Supplementation for Caries Prophylaxis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nicotinic Acid","generic_name":"NIACIN","company_name":"MEDPOINTE PHARM HLC","drug_phase":"marketed","molecular_target":"NAD synthase","drug_class":"Vitamin C [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"tafenoquine","indication_name":"Malaria Prophylaxis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Krintafel","generic_name":"TAFENOQUINE","company_name":"60 Degrees Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"tafenoquine","quality_score":55,"revenue":null,"mechanism":"Tafenoquine works by targeting the parasite's heme detoxification pathway, preventing the parasite from producing heme and ultimately leading to its death."},{"drug_id":"atovaquone-and-proguanil","indication_name":"Prophylaxis of P. falciparum malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Atovaquone and Proguanil","company_name":"State University of New York - Upstate Medical University","drug_phase":"marketed","molecular_target":"","drug_class":"Antimalarial [EPC]","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"posaconazole","indication_name":"Prophylaxis of Invasive Aspergillus and Candida Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"POSACONAZOLE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Azole Antifungal [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"anti-thymocyte-globulin","indication_name":"Prophylaxis and treatment of acute rejection in kidney transplant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Anti Thymocyte Globulin","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"","drug_class":"Immunoglobulin G [EPC]","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"factor-ix","indication_name":"Routine prophylaxis to reduce the frequency of bleeding episodes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"factor ix","company_name":"National Heart, Lung, and Blood Institute (NHLBI)","drug_phase":"marketed","molecular_target":"coagulation Factor IX","drug_class":"","quality_score":55,"revenue":null,"mechanism":"REBINYN replaces missing coagulation Factor IX and slows its removal from circulation through PEGylation."},{"drug_id":"berotralstat-hydrochloride","indication_name":"Prophylaxis to prevent HAE attacks","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"BEROTRALSTAT HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"plasma kallikrein","drug_class":"","quality_score":45,"revenue":null,"mechanism":"Berotralstat inhibits plasma kallikrein to reduce bradykinin generation and control angioedema in HAE."},{"drug_id":"cefuroxime-sodium","indication_name":"Preoperative Prophylaxis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFUROXIME SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Cefuroxime inhibits bacterial cell wall synthesis, acting as a bactericidal agent."},{"drug_id":"doxycycline","indication_name":"Malaria prophylaxis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vibramycin","generic_name":"doxycycline","company_name":"Generic (originally Pfizer)","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"Tetracycline antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bacillus-calmette-guerin","indication_name":"Treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bacillus-calmette-guerin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Mycobacterium tuberculosis","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"bacillus-calmette-guerin","indication_name":"Prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bacillus-calmette-guerin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Mycobacterium tuberculosis","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"bacillus-calmette-guerin","indication_name":"Prophylaxis of stage TaG1 papillary tumors at high risk of tumor recurrence","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bacillus-calmette-guerin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Mycobacterium tuberculosis","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"spiramycin","indication_name":"Prophylaxis of congenital toxoplasmosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rovamycin","generic_name":"SPIRAMYCIN","company_name":"Sanofi KK","drug_phase":"marketed","molecular_target":"","drug_class":"spiramycin","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"baloxavir","indication_name":"Post-exposure prophylaxis of influenza","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xofluza","generic_name":"BALOXAVIR","company_name":"Genentech Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":52,"revenue":null,"mechanism":"Xofluza works by inhibiting the endonuclease activity of the influenza virus, preventing it from replicating."},{"drug_id":"baloxavir","indication_name":"Post-Exposure Prophylaxis of Influenza","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xofluza","generic_name":"BALOXAVIR","company_name":"Genentech Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":52,"revenue":null,"mechanism":"Xofluza works by inhibiting the endonuclease activity of the influenza virus, preventing it from replicating."},{"drug_id":"hympavzi","indication_name":"Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hympavzi","generic_name":"Marstacimab-Hncq","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Tissue Factor Pathway Inhibitor (TFPI) Kunitz domain 2 (K2)","drug_class":"Tissue Factor Pathway Inhibitor (TFPI) Antagonist","quality_score":65,"revenue":null,"mechanism":"Monoclonal antibody against TFPI Kunitz domain 2 to neutralize TFPI and enhance coagulation."},{"drug_id":"hympavzi","indication_name":"Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia B (congenital factor IX deficiency) without factor IX inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hympavzi","generic_name":"Marstacimab-Hncq","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Tissue Factor Pathway Inhibitor (TFPI) Kunitz domain 2 (K2)","drug_class":"Tissue Factor Pathway Inhibitor (TFPI) Antagonist","quality_score":65,"revenue":null,"mechanism":"Monoclonal antibody against TFPI Kunitz domain 2 to neutralize TFPI and enhance coagulation."},{"drug_id":"verapamil-hydrochloride","indication_name":"Prophylaxis of repetitive paroxysmal supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Verapamil Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channels (slow channels)","drug_class":"Calcium channel blocker","quality_score":56,"revenue":null,"mechanism":"Calcium ion influx inhibitor that modulates ionic calcium across cell membranes of arterial smooth muscle and myocardial cells."},{"drug_id":"vitamin-k1","indication_name":"Prophylaxis of hemorrhagic disease of the newborn","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitamin K1","generic_name":"Phytonadione","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Vitamin K-dependent carboxylase; vitamin K epoxide reductase complex (indirect antagonism of warfarin effects)","drug_class":"Vitamin K [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"fragmin","indication_name":"Prophylaxis of ischemic complications in unstable angina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fragmin","generic_name":"Dalteparin Sodium","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Factor Xa and thrombin","drug_class":"Low molecular weight heparin (LMWH)","quality_score":68,"revenue":null,"mechanism":"Dalteparin enhances inhibition of Factor Xa and thrombin by antithrombin."},{"drug_id":"fragmin","indication_name":"Prophylaxis of ischemic complications in non-Q-wave myocardial infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fragmin","generic_name":"Dalteparin Sodium","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Factor Xa and thrombin","drug_class":"Low molecular weight heparin (LMWH)","quality_score":68,"revenue":null,"mechanism":"Dalteparin enhances inhibition of Factor Xa and thrombin by antithrombin."},{"drug_id":"fragmin","indication_name":"Prophylaxis of deep vein thrombosis in patients undergoing hip replacement surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fragmin","generic_name":"Dalteparin Sodium","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Factor Xa and thrombin","drug_class":"Low molecular weight heparin (LMWH)","quality_score":68,"revenue":null,"mechanism":"Dalteparin enhances inhibition of Factor Xa and thrombin by antithrombin."},{"drug_id":"fragmin","indication_name":"Prophylaxis of deep vein thrombosis in patients undergoing abdominal surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fragmin","generic_name":"Dalteparin Sodium","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Factor Xa and thrombin","drug_class":"Low molecular weight heparin (LMWH)","quality_score":68,"revenue":null,"mechanism":"Dalteparin enhances inhibition of Factor Xa and thrombin by antithrombin."},{"drug_id":"fragmin","indication_name":"Prophylaxis of deep vein thrombosis in medical patients with severely restricted mobility during acute illness","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fragmin","generic_name":"Dalteparin Sodium","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Factor Xa and thrombin","drug_class":"Low molecular weight heparin (LMWH)","quality_score":68,"revenue":null,"mechanism":"Dalteparin enhances inhibition of Factor Xa and thrombin by antithrombin."},{"drug_id":"phytonadione","indication_name":"Prophylaxis and therapy of hemorrhagic disease of the newborn","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PHYTONADIONE","company_name":"","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1 (VKORC1)","drug_class":"Vitamin K [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"potassium","indication_name":"treatment and prophylaxis of hypokalemia with or without metabolic alkalosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Chloride","generic_name":"POTASSIUM","company_name":"Nesher Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Potassium Chloride works by replenishing potassium levels in the body."},{"drug_id":"verapamil-hydrochloride","indication_name":"Prophylaxis of paroxysmal supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Verapamil Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channels (slow channels)","drug_class":"Calcium channel blocker","quality_score":56,"revenue":null,"mechanism":"Calcium ion influx inhibitor that modulates ionic calcium across cell membranes of arterial smooth muscle and myocardial cells."},{"drug_id":"potassium","indication_name":"treatment and prophylaxis of hypokalemia with or without metabolic alkalosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Chloride","generic_name":"POTASSIUM","company_name":"Nesher Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Potassium Chloride works by replenishing potassium levels in the body."}],"pipeline":[],"offLabel":[],"totalMarketed":40,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06020560","title":"Study of Low Molecular Weight Heparins","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":65000,"lead_sponsor_name":"Herlev Hospital","has_results":false},{"nct_id":"NCT01865799","title":"A Prospective, Observational, Drug Utilization Study of Subjects Taking Truvada for Pre-exposure Prophylaxis in the USA","phase":"","overall_status":"COMPLETED","enrollment_count":64186,"lead_sponsor_name":"Gilead Sciences","has_results":false},{"nct_id":"NCT07089966","title":"HIV Testing Counselor-led Care to Catalyze Integration of PrEP Delivery in Family Planning Clinics","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":30000,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT05874869","title":"Dihydroartemisinin-piperaquine for Seasonal Malaria Chemoprophylaxis in Tanzania","phase":"NA","overall_status":"COMPLETED","enrollment_count":13800,"lead_sponsor_name":"Richard Mwaiswelo","has_results":false},{"nct_id":"NCT06319105","title":"PathToScale: An Implementation Evaluation","phase":"","overall_status":"UNKNOWN","enrollment_count":9900,"lead_sponsor_name":"Georgetown University","has_results":false},{"nct_id":"NCT06647797","title":"Enhancing Communication on Relationship Preservation, Safer Conception and PrEP to Promote HIV Testing in Uganda","phase":"NA","overall_status":"COMPLETED","enrollment_count":7666,"lead_sponsor_name":"Children's Mercy Hospital Kansas City","has_results":false},{"nct_id":"NCT05482360","title":"Testing Implementation Strategies to Improve Delivery of PrEP for Pregnant and Postpartum Women in Kenya","phase":"NA","overall_status":"COMPLETED","enrollment_count":5173,"lead_sponsor_name":"University of Washington","has_results":true},{"nct_id":"NCT07071623","title":"A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":4580,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT07044297","title":"A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":4390,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT04379245","title":"COVID-19 Infection in Patients Infected With HIV and/or on PrEP","phase":"","overall_status":"COMPLETED","enrollment_count":4200,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT04979780","title":"Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort","phase":"","overall_status":"COMPLETED","enrollment_count":3708,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06408142","title":"Universal Test and Connect for HIV Service Delivery in South Africa","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT04712994","title":"PrEPARE: PrEP in Pregnancy, Accelerating Reach and Efficiency","phase":"NA","overall_status":"COMPLETED","enrollment_count":1958,"lead_sponsor_name":"University of Washington","has_results":true},{"nct_id":"NCT03283878","title":"Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty- Multi-center Trial","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1770,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT04363450","title":"Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":1700,"lead_sponsor_name":"Louisiana State University Health Sciences Center in New Orleans","has_results":false},{"nct_id":"NCT01504347","title":"Phase 1/2 Lyme Vaccine Study","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":1630,"lead_sponsor_name":"Baxalta now part of Shire","has_results":false},{"nct_id":"NCT06947707","title":"Safety and Efficacy of Edoxaban and Rivaroxaban to Cerebral Venous Thrombosis in Chinese Patients","phase":"","overall_status":"RECRUITING","enrollment_count":1486,"lead_sponsor_name":"Xuanwu Hospital, Beijing","has_results":false},{"nct_id":"NCT07160686","title":"Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":1456,"lead_sponsor_name":"University of Birmingham","has_results":false},{"nct_id":"NCT06195540","title":"RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1424,"lead_sponsor_name":"University Hospital, Angers","has_results":false},{"nct_id":"NCT04754139","title":"A Promotion and Implementation Project of HIV Pre-Exposure Prophylaxis Among High Risk Population","phase":"NA","overall_status":"COMPLETED","enrollment_count":1200,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT05846568","title":"Study to Evaluate GR1801's Efficacy and Safety","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1200,"lead_sponsor_name":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05571722","title":"Linezolid or Vancomycin Surgical Site Infection Prophylaxis","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":1160,"lead_sponsor_name":"Assistance Publique Hopitaux De Marseille","has_results":false},{"nct_id":"NCT03565575","title":"Manicaland PrEP Uptake Through Interactive Counselling Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":1055,"lead_sponsor_name":"Simon Gregson","has_results":false},{"nct_id":"NCT04557241","title":"Brief Informational Intervention for COVID-19 Misinformation Prophylaxis","phase":"NA","overall_status":"COMPLETED","enrollment_count":1017,"lead_sponsor_name":"Indiana University","has_results":false},{"nct_id":"NCT07244432","title":"Post-ERCP Pancreatitis - Prophylactic Measures Implementation Study (PEP-PROMIS)","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Branislav Kuncak","has_results":false},{"nct_id":"NCT06286527","title":"Quality of Sexual Life of PrEP Users","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University Hospital, Grenoble","has_results":false},{"nct_id":"NCT03996941","title":"Harm Reduction Program For Informal PrEP Users In A Community-based Setting (seguiPrEP)","phase":"","overall_status":"UNKNOWN","enrollment_count":900,"lead_sponsor_name":"BCN Checkpoint","has_results":false},{"nct_id":"NCT03308968","title":"An Efficacy and Safety Study of Fremanezumab in Adults With Migraine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":838,"lead_sponsor_name":"Teva Branded Pharmaceutical Products R&D, Inc.","has_results":true},{"nct_id":"NCT04424524","title":"Streamlining the Efficiency of PrEP Implementation","phase":"NA","overall_status":"COMPLETED","enrollment_count":746,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT04644029","title":"Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":730,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03633643","title":"Cotrimoxazole Prophylaxis in Transurethral Resection or Greenlight Laser Vaporisation of the Prostate","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":728,"lead_sponsor_name":"University Hospital, Basel, Switzerland","has_results":false},{"nct_id":"NCT05670860","title":"Comitial Prophylaxis in Neurosurgery in Patients Who Have Undergone Intracranial Surgery Programmed Supratentorial Surgery (Exeresis or Biopsy) Between 2019 and 2022","phase":"","overall_status":"UNKNOWN","enrollment_count":700,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT04368559","title":"Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":602,"lead_sponsor_name":"Mundipharma Research Limited","has_results":false},{"nct_id":"NCT05417620","title":"Le Kip Kip: A Campaign to Change Social Norms and Build Sustainable Demand for PrEP Among Women in South Africa","phase":"NA","overall_status":"COMPLETED","enrollment_count":601,"lead_sponsor_name":"Johns Hopkins Bloomberg School of Public Health","has_results":true},{"nct_id":"NCT00919152","title":"Economic Outcomes of Enteral and Parenteral Proton Pump Inhibitor (PPI) Use in the Intensive Care Unit (ICU)","phase":"","overall_status":"COMPLETED","enrollment_count":534,"lead_sponsor_name":"University of Nebraska","has_results":false},{"nct_id":"NCT04816461","title":"Boosting the Impact of SMC Through Simultaneous Screening and Treatment of Roommates","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":526,"lead_sponsor_name":"Institut de Recherche en Sciences de la Sante, Burkina Faso","has_results":false},{"nct_id":"NCT03790254","title":"D Mannose for Prevention and Treatment of RUTIs","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Fondazione IRCCS Policlinico San Matteo di Pavia","has_results":false},{"nct_id":"NCT03098537","title":"Effects of Enteral Nutrition on Stress Ulcer Hemorrage. Multicenter Randomized Controlled Trial","phase":"NA","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"TC Erciyes University","has_results":false},{"nct_id":"NCT06136442","title":"Atogepant in Real Life in Italy (GIANT)","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"IRCCS San Raffaele Roma","has_results":false},{"nct_id":"NCT05986084","title":"Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Beth Israel Deaconess Medical Center","has_results":false},{"nct_id":"NCT06620263","title":"Stress Ulcer Prophylaxis Practices in the Intensive Care Unit","phase":"","overall_status":"COMPLETED","enrollment_count":495,"lead_sponsor_name":"Yunus Emre AYHAN","has_results":false},{"nct_id":"NCT04652700","title":"Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":494,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT06742567","title":"Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":472,"lead_sponsor_name":"National Institute of Cardiovascular Diseases, Pakistan","has_results":false},{"nct_id":"NCT03028129","title":"Prevention of Tuberculosis in Prisons","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":467,"lead_sponsor_name":"Federal University of Mato Grosso","has_results":true},{"nct_id":"NCT05856942","title":"Hybrid Evaluation of a Home-based HIV Pre-exposure Prophylaxis Program","phase":"NA","overall_status":"RECRUITING","enrollment_count":458,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT04999176","title":"Venous Thromboembolism Prophylaxis After Gynecological Pelvic Cancer Surgery With Rivaroxaban vs Enoxaparin","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":440,"lead_sponsor_name":"André Luiz Malavasi Longo de Oliveira","has_results":false},{"nct_id":"NCT05095818","title":"Impact of Nursing Involvement on Implementation of HIV Prevention Services","phase":"NA","overall_status":"COMPLETED","enrollment_count":440,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT04222504","title":"Community-based Venues for Delivery of Healthcare Services: Proof of Concept Pilot","phase":"NA","overall_status":"COMPLETED","enrollment_count":436,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT06647173","title":"The Blued+ Combination HIV Prevention Pilot Study in China","phase":"","overall_status":"COMPLETED","enrollment_count":423,"lead_sponsor_name":"Emory University","has_results":true},{"nct_id":"NCT04092114","title":"CHARISMA Expansion Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":407,"lead_sponsor_name":"RTI International","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}